239 related articles for article (PubMed ID: 16982549)
1. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.
Kavanagh BD; Schefter TE; Cardenes HR; Stieber VW; Raben D; Timmerman RD; McCarter MD; Burri S; Nedzi LA; Sawyer TE; Gaspar LE
Acta Oncol; 2006; 45(7):848-55. PubMed ID: 16982549
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Rusthoven KE; Kavanagh BD; Cardenes H; Stieber VW; Burri SH; Feigenberg SJ; Chidel MA; Pugh TJ; Franklin W; Kane M; Gaspar LE; Schefter TE
J Clin Oncol; 2009 Apr; 27(10):1572-8. PubMed ID: 19255321
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.
Rusthoven KE; Kavanagh BD; Burri SH; Chen C; Cardenes H; Chidel MA; Pugh TJ; Kane M; Gaspar LE; Schefter TE
J Clin Oncol; 2009 Apr; 27(10):1579-84. PubMed ID: 19255320
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.
Méndez Romero A; Wunderink W; Hussain SM; De Pooter JA; Heijmen BJ; Nowak PC; Nuyttens JJ; Brandwijk RP; Verhoef C; Ijzermans JN; Levendag PC
Acta Oncol; 2006; 45(7):831-7. PubMed ID: 16982547
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiotherapy of primary liver cancer and hepatic metastases.
Wulf J; Guckenberger M; Haedinger U; Oppitz U; Mueller G; Baier K; Flentje M
Acta Oncol; 2006; 45(7):838-47. PubMed ID: 16982548
[TBL] [Abstract][Full Text] [Related]
6. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.
Scorsetti M; Arcangeli S; Tozzi A; Comito T; Alongi F; Navarria P; Mancosu P; Reggiori G; Fogliata A; Torzilli G; Tomatis S; Cozzi L
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):336-42. PubMed ID: 23433800
[TBL] [Abstract][Full Text] [Related]
7. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
9. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of individualized stereotactic body radiotherapy of liver metastases.
Lee MT; Kim JJ; Dinniwell R; Brierley J; Lockwood G; Wong R; Cummings B; Ringash J; Tse RV; Knox JJ; Dawson LA
J Clin Oncol; 2009 Apr; 27(10):1585-91. PubMed ID: 19255313
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases.
McPartlin A; Swaminath A; Wang R; Pintilie M; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):388-395. PubMed ID: 28871989
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiation therapy for liver metastases: factors affecting local control and survival.
Andratschke NH; Nieder C; Heppt F; Molls M; Zimmermann F
Radiat Oncol; 2015 Mar; 10():69. PubMed ID: 25889512
[TBL] [Abstract][Full Text] [Related]
14. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
[TBL] [Abstract][Full Text] [Related]
17. Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases.
Swaminath A; Massey C; Brierley JD; Dinniwell R; Wong R; Kim JJ; Velec M; Brock KK; Dawson LA
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):639-48. PubMed ID: 26461006
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.
Schefter TE; Kavanagh BD; Timmerman RD; Cardenes HR; Baron A; Gaspar LE
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1371-8. PubMed ID: 16029795
[TBL] [Abstract][Full Text] [Related]
19. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.
Stera S; Balermpas P; Chan MKH; Huttenlocher S; Wurster S; Keller C; Imhoff D; Rades D; Dunst J; Rödel C; Hildebrandt G; Blanck O
Strahlenther Onkol; 2018 Feb; 194(2):143-155. PubMed ID: 28875297
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
